Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
NDC API
0
VMF
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. (r)-9-(2-phosphonylmethoxypropyl)adenine
2. 9-(2-phosphonomethoxypropyl)adenine
3. 9-(2-phosphonylmethoxypropyl)adenine
4. 9-(2-phosphonylmethoxypropyl)adenine, (+-)-isomer
5. 9-(2-phosphonylmethoxypropyl)adenine, (r)-isomer - T357098
6. 9-(2-phosphonylmethoxypropyl)adenine, (s)-isomer
7. 9-pmpa (tenofovir)
8. Disoproxil Fumarate, Tenofovir
9. Disoproxil, Tenofovir
10. Fumarate, Tenofovir Disoproxil
11. Tenofovir Disoproxil
12. Tenofovir Disoproxil Fumarate
13. Viread
1. 147127-20-6
2. (r)-9-(2-phosphonomethoxypropyl)adenine
3. Truvada
4. (r)-pmpa
5. Tenofovir (anhydrous)
6. Pmpa Gel
7. (r)-(((1-(6-amino-9h-purin-9-yl)propan-2-yl)oxy)methyl)phosphonic Acid
8. Apropovir
9. Gs-1275
10. Anhydrous Tenofovir
11. Tenofovir Anhydrous
12. Tenofovir (anh.)
13. Chebi:63625
14. Pmp-a
15. [(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic Acid
16. ({[(2r)-1-(6-amino-9h-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic Acid
17. W4hfe001u5
18. (r)-(1-(6-amino-9h-purin-9-yl)propan-2-yloxy)methylphosphonic Acid
19. 147127-20-6 (tenofovir)
20. Gs-1278
21. 9-[(r)-2-(phosphonomethoxy)propyl]adenine
22. Phosphonic Acid, P-[[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]-
23. D,l-tenofovir
24. Tenofovir Gel
25. [(1r)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methylphosphonic Acid
26. (((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)phosphonic Acid
27. (r)-[[2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]phosphonic Acid
28. {[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl}phosphonic Acid
29. Gna & Tenofovir
30. Hha & Tenofovir
31. Tfv Gel
32. Gs 1275
33. Pmpa-(r)
34. Unii-w4hfe001u5
35. Tenofovir [usan:inn:ban]
36. Rac Tenofovir
37. Anh. Tenofovir
38. Viread (prodrug For Tenofovir)
39. Phosphonic Acid, (((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-
40. Phosphonic Acid, [[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]-
41. Phosphonic Acid, P-(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-
42. Tenofovir- Bio-x
43. Tenofovir (viread)
44. (r)-9-(phosphonomethoxypropyl)adenine
45. Gs 1278
46. Ks-5021
47. Tenofovir [inn]
48. Tenofovir [mi]
49. 9-pmpa
50. Chembl483
51. Ec 604-571-2
52. Tenofovir [who-dd]
53. Schembl39724
54. Tenofovir Gel (gs-1278)
55. Dtxsid9040132
56. Tenofovir, >=98% (hplc)
57. Gtpl10948
58. Bcpp000049
59. Hms3264h05
60. Zinc1543475
61. Ac-760
62. Bdbm50450813
63. Mfcd00943794
64. Akos015856701
65. Akos015894941
66. Ccg-267345
67. Cs-1609
68. Db14126
69. Phosphonic Acid, ((2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-, (r)-
70. Ncgc00167535-16
71. Bt164455
72. Hy-13910
73. (r)-9-(2-phosphonoylmethoxypropyl)adenine
74. Am20090678
75. T3006
76. (r)-9-[2-(phosphonomethoxy) Propyl] Adenine
77. C17407
78. Ab01274787-01
79. Ab01274787_02
80. Ab01274787_03
81. 127t206
82. A808613
83. Q155954
84. Sr-01000883934
85. Q-201787
86. Sr-01000883934-1
87. Brd-k15891719-001-02-8
88. [(2r)-3-(6-aminopurin-9-yl)-2-methyl-propyl] Dihydrogen Phosphate
89. [[(1r)-2(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]phosphonic Acid
90. [2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methylphosphonic Acid
91. Phosphonic Acid, [[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus Nivalis Agglutinin (gna)
92. Phosphonic Acid, [[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum Hybrid Agglutinin( Hha)
| Molecular Weight | 287.21 g/mol |
|---|---|
| Molecular Formula | C9H14N5O4P |
| XLogP3 | -1.6 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 287.07834094 g/mol |
| Monoisotopic Mass | 287.07834094 g/mol |
| Topological Polar Surface Area | 136 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 354 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus. To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, [tenofovir alafenamide] and [tenofovir disoproxil].
Treatment of HIV-1 infection:
- Truvada is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.
- Truvada is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.
Pre-exposure prophylaxis (PrEP):
- Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
Tenofovir has been shown to be highly effective in patients that have never had an antiretroviral therapy and it seemed to have lower toxicity than other antivirals such as [stavudine]. In phase 3 clinical trials, tenofovir presented a similar efficacy than [efavirenz] in treatment-naive HIV patients. In hepatitis B infected patients, after one year of tenofovir treatment, the viral DNA levels were undetectable.
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
Anti-HIV Agents
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)
Reverse Transcriptase Inhibitors
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)
J05AR03
Absorption
Tenofovir as the active moiety presents a very low bioavailability when orally administered. Hence, the administration of this active agent is required to be under its two prodrug forms, [tenofovir disoproxil] and [tenofovir alafenamide]. This reduced absorption is suggested to be related to the presence of two negative charges among its structure. This negative charge limits its cellular penetration, and its passive diffusion across cellular membranes and intestinal mucosa hindering its availability for oral administration. Intravenous tenofovir has been shown to produce a maximum plasma concentration of 2500 ng/ml with an AUC of 4800 ng.h/ml.
Route of Elimination
Tenofovir is eliminated in the urine by tubular secretion and glomerular filtration. The elimination of this compound is driven by the activity of the human organic anion transporters 1 and 3 and its secretion is mainly ruled by the activity of the multidrug resistance-associated protein 4.
Volume of Distribution
Accumulation of tenofovir in plasma is related to the presence of nephrotoxic effects. It is reported that tenofovir presents a volume of distribution of 0.813 L/kg.
Clearance
The clearance of tenofovir is highly dependent on the patient renal stage and hence the clearance rate in patients with renal impairment is reported to be of 134 ml/min while in patients with normal function the clearance rate can be of 210 ml/min.
Tenofovir activation is performed by a bi-phosphorylation which in order forms the biologically active compound, tenofovir biphosphate. This metabolic activation has been shown to be performed in hepG2 cells and human hepatocytes.
The reported half-life of tenofovir is of 32 hours.
Once tenofovir is activated by a bi-phosphorylation it acts as an antiviral acyclic nucleoside phosphonate. It is a potent inhibitor of the viral reverse transcriptase with an inhibitory constant of approximately 0.022 micromolar. Once activated, tenofovir acts with different mechanisms including the inhibition of viral polymerase causing chain termination and the inhibition of viral synthesis. All these activities are attained by its competition with deoxyadenosine 5'-triphosphate in the generation of new viral DNA. Once tenofovir is incorporated in the chain, it induces a chain termination which in order inhibits viral replication. The safety of tenofovir relies on its low affinity towards the cellular DNA polymerase including the mitochondrial DNA polymerase gamma.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.
L-Alanine isopropyl ester, HCl
CAS Number : 62062-65-1
End Use API : Tenofovir
About The Company : PMC Isochem is a CDMO company acquired by PMC International in 2017. It manufactures cGMP intermediates, active pharmaceutical ingredients and functional excipi...
(R)-9-(2-hydroxypropyl) adenine
CAS Number : 14047-28-0
End Use API : Tenofovir
About The Company : Berr Chemical Company Ltd is a high-tech enterprise engaged in Pharmaceuctials; azepan products;Pyrimidine products;Piperazines products;Pyridine products;Piper...
L-AIanine isopropyl ester hydrochloride
CAS Number : 62062-65-1
End Use API : Tenofovir
About The Company : Bulat Pharmaceutical is a fast growing pharmaceutical company, founded in the year 2017, Bulat Pharmaceutical is engaged in the manufacturing and sales of high ...
Diethyl (tosyloxy)methylphosphonate
CAS Number : 31618-90-3
End Use API : Tenofovir
About The Company : Chengda Pharmaceutical Co., Ltd. was founded in 1999. It is located in the Hangzhou-Jiaxing-Huzhou plain, Jiashan Economic & Technological Development Zone (nat...
CAS Number :
End Use API : Tenofovir
About The Company : Dorrapharma is engaged in R&D, manufacture and market of intermediate, API (Active Pharmaceutical Ingredients) and formulation. We stick to raise the value both...
9-[(R)-2-(Phosphonomethoxy)propyl]adenine monohydr...
CAS Number : 206184-49-8
End Use API : Tenofovir
About The Company : Sandoo Pharmaceuticals and Chemcials Co.,Ltd was established in 2009, with a young and active team, located in Ningbo, China. Specializes in exporting and imp...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
40
PharmaCompass offers a list of Tenofovir API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tenofovir manufacturer or Tenofovir supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tenofovir manufacturer or Tenofovir supplier.
PharmaCompass also assists you with knowing the Tenofovir API Price utilized in the formulation of products. Tenofovir API Price is not always fixed or binding as the Tenofovir Price is obtained through a variety of data sources. The Tenofovir Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Tenofovir Hydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tenofovir Hydrate, including repackagers and relabelers. The FDA regulates Tenofovir Hydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tenofovir Hydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tenofovir Hydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tenofovir Hydrate supplier is an individual or a company that provides Tenofovir Hydrate active pharmaceutical ingredient (API) or Tenofovir Hydrate finished formulations upon request. The Tenofovir Hydrate suppliers may include Tenofovir Hydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Tenofovir Hydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tenofovir Hydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Tenofovir Hydrate active pharmaceutical ingredient (API) in detail. Different forms of Tenofovir Hydrate DMFs exist exist since differing nations have different regulations, such as Tenofovir Hydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tenofovir Hydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Tenofovir Hydrate USDMF includes data on Tenofovir Hydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tenofovir Hydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tenofovir Hydrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Tenofovir Hydrate Drug Master File in Japan (Tenofovir Hydrate JDMF) empowers Tenofovir Hydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Tenofovir Hydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Tenofovir Hydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Tenofovir Hydrate suppliers with JDMF on PharmaCompass.
A Tenofovir Hydrate written confirmation (Tenofovir Hydrate WC) is an official document issued by a regulatory agency to a Tenofovir Hydrate manufacturer, verifying that the manufacturing facility of a Tenofovir Hydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tenofovir Hydrate APIs or Tenofovir Hydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Tenofovir Hydrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Tenofovir Hydrate suppliers with Written Confirmation (WC) on PharmaCompass.
Tenofovir Hydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tenofovir Hydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tenofovir Hydrate GMP manufacturer or Tenofovir Hydrate GMP API supplier for your needs.
A Tenofovir Hydrate CoA (Certificate of Analysis) is a formal document that attests to Tenofovir Hydrate's compliance with Tenofovir Hydrate specifications and serves as a tool for batch-level quality control.
Tenofovir Hydrate CoA mostly includes findings from lab analyses of a specific batch. For each Tenofovir Hydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tenofovir Hydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Tenofovir Hydrate EP), Tenofovir Hydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tenofovir Hydrate USP).
